Moderna Raises Full-Year COVID Vaccine Sales Forecast to $21 Billion

By Reuters
Reuters
Reuters
March 25, 2022 Updated: March 25, 2022

Moderna Inc on Thursday raised its full-year forecast for sales of its COVID-19 vaccine to roughly $21 billion from $19 billion.

The company in February forecast sales of $19 billion from its signed contracts, and option for $3 billion in additional purchases.

Moderna on Thursday forecast additional purchases of roughly $500 million.

 

Reuters